European Journal of Cardiovascular Medicine

Material & Methods: Study Design:  Case-control study. Study area: Department of General Medicine, Nimra Institute of Medical Sciences, Vijayawada. Andhra Pradesh. Study Period: April 2022 – March 2023. Study population:  Patients with acute myocardial infarction admitted in department of medicine. Sample size: Study consisted a total of 50 cases and 10 controls. Sampling Technique:  Simple random method. Study tools and Data collection procedure: 50 acute myocardial infarction cases and 10 healthy controls were selected. The subjects were informed about the nature and purpose of the study and consent was taken from subjects themselves or family members in case of unconscious patients. Patients presenting with chest pain suggestive of myocardial infarction, who showed E.C.G. evidence of acute infarction changes were assessed by detailed history and physical examination as outlined in proforma. The infarction was confirmed by elevated CPK/troponin levels. Serum magnesium is estimated within first 24 hours of chest pain. Serum magnesium estimated by Colorimetric method using calmagite. Clinical findings, and serum magnesium levels are used as parameters to assess the incidence of complications likes arrhythmias, left ventricular failure, cardiogenic shock, supraventricular arrhythmias. Bundle Branch Block, Hemi Block, AV Block and Mortality in patients with AMI. Results: There were more number of deaths in AMI patients with hypomagnesemia than in patients of AMI with normal serum magnesium levels. There is no statistically significant association of hypomagnesemia with death in cases of AMI as p value is 0.091. Conclusion: Prophylactic administration of the intravenous magnesium sulphate may be considered in all cases of Acute Myocardial infarction as an adjuvant to thrombolytic therapy and in patients not suitable for thrombolysis to prevent cardiac arrhythmias & reduce short term mortality irrespective of serum magnesium levels as it is safe and cheap.